loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Ziftomenib

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Ziftomenib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Kura Oncology Publishes Ziftomenib Ph 1 Results In The Lancet
    Kura Oncology Publishes Ziftomenib Ph 1 Results In The Lancet

    30 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/en/news-release/2024/09/30/2955703/35186/en/Kura-Oncology-Announces-Publication-of-Ziftomenib-Phase-1-Results-in-The-Lancet-Oncology.html

    GLOBENEWSWIRE
    30 Sep 2024
    Share Share
    Kura Oncology Announces FDA Clearance Of IND For Ziftomenib In GIST
    Kura Oncology Announces FDA Clearance Of IND For Ziftomenib In GIST

    08 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/08/2926821/35186/en/Kura-Oncology-Announces-FDA-Clearance-of-IND-Application-for-Menin-Inhibitor-Ziftomenib-in-Advanced-Gastrointestinal-Stromal-Tumors-GIST.html

    GLOBENEWSWIRE
    08 Aug 2024
    Share Share
    Kura Reports Preclinical Data on Menin Inhibitor's Potential in Diabetes
    Kura Reports Preclinical Data on Menin Inhibitor's Potential in Diabetes

    24 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/24/2902881/35186/en/Kura-Oncology-Reports-Preclinical-Data-Supporting-Potential-for-Menin-Inhibitor-in-Diabetes.html

    GLOBENEWSWIRE
    24 Jun 2024
    Share Share
    Kura Completes Ziftomenib NPM1-Mutant AML Trial Enrollment
    Kura Completes Ziftomenib NPM1-Mutant AML Trial Enrollment

    14 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/14/2881267/35186/en/Kura-Oncology-Completes-Enrollment-in-Registration-Directed-Trial-of-Ziftomenib-in-NPM1-Mutant-AML.html

    GLOBENEWSWIRE
    14 May 2024
    Share Share
    Kura Oncology Reports First Quarter 2024 Financial Results
    Kura Oncology Reports First Quarter 2024 Financial Results

    02 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/02/2874668/35186/en/Kura-Oncology-Reports-First-Quarter-2024-Financial-Results.html

    GLOBENEWSWIRE
    02 May 2024
    Share Share
    Kura Gets Ziftomenib BTD In NPM1-Mutant AML
    Kura Gets Ziftomenib BTD In NPM1-Mutant AML

    22 Apr 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/04/22/2866763/35186/en/Kura-Oncology-Receives-Breakthrough-Therapy-Designation-for-Ziftomenib-in-NPM1-Mutant-AML.html

    GLOBENEWSWIRE
    22 Apr 2024
    Share Share